Clinical trialNCT07431177RecruitingPhase 2Interventional

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

SponsorNovartis PharmaceuticalsEnrollment210Non-segmental Vitiligo

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

72 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Novartis Investigative Site
Caba, Buenos Aires, Argentina
Recruiting

Australia

Novartis Investigative Site
Sydney, New South Wales, Australia
Recruiting
Novartis Investigative Site
Waitara, New South Wales, Australia
Recruiting
Novartis Investigative Site
Melbourne, Victoria, Australia
Recruiting

Canada

Novartis Investigative Site
Calgary, Alberta, Canada
Recruiting
Novartis Investigative Site
Winnipeg, Manitoba, Canada
Recruiting
Novartis Investigative Site
Mississauga, Ontario, Canada
Recruiting
Novartis Investigative Site
Newmarket, Ontario, Canada
Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada
Recruiting
Novartis Investigative Site
Québec, Quebec, Canada
Recruiting

China

Novartis Investigative Site
Guangzhou, Guangdong, China
Recruiting
Novartis Investigative Site
Wuhan, Hubei, China
Recruiting
Novartis Investigative Site
Beijing, China
Recruiting
Novartis Investigative Site
Shanghai, China
Recruiting

France

Novartis Investigative Site
Bordeaux, France
Recruiting
Novartis Investigative Site
Brest, France
Recruiting
Novartis Investigative Site
Créteil, France
Recruiting
Novartis Investigative Site
Nice, France
Recruiting
Novartis Investigative Site
Reims, France
Recruiting
Novartis Investigative Site
Rouen, France
Recruiting
Novartis Investigative Site
Toulouse, France
Recruiting

Germany

Novartis Investigative Site
Munich, Bavaria, Germany
Recruiting
Novartis Investigative Site
Bad Bentheim, Germany
Recruiting
Novartis Investigative Site
Bielefeld, Germany
Recruiting
Novartis Investigative Site
Hamburg, Germany
Recruiting
Novartis Investigative Site
Hanover, Germany
Recruiting
Novartis Investigative Site
Lübeck, Germany
Recruiting
Novartis Investigative Site
Münster, Germany
Recruiting
Novartis Investigative Site
Tübingen, Germany
Recruiting

India

Novartis Investigative Site
Ahmedabad, Gujarat, India
Recruiting
Novartis Investigative Site
Bangalore, Karnataka, India
Recruiting
Novartis Investigative Site
Belagavi, Karnataka, India
Recruiting
Novartis Investigative Site
Mysore, Karnataka, India
Recruiting
Novartis Investigative Site
Nashik, Maharashtra, India
Recruiting

Italy

Novartis Investigative Site
Ancona, AN, Italy
Recruiting
Novartis Investigative Site
Cona, FE, Italy
Recruiting
Novartis Investigative Site
Milan, MI, Italy
Recruiting
Novartis Investigative Site
Rozzano, MI, Italy
Recruiting

Japan

Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Recruiting
Novartis Investigative Site
Urayasu, Chiba, Japan
Recruiting

32 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

GIA632Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 Mar 2026
Primary completion: 6 Jun 2028
Completion: 28 Jan 2030
Last update posted: 19 Aug 2026
Registered enrollment: 210
Registry id: NCT07431177

Cross-registrations

EU-CTR / CTIS (EudraCT)2025-522301-37-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.